Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ).
ResMed Inc has reported a change in beneficial ownership as Harjit Gill, a director and 10% owner, acquired 1,073 shares of ResMed common stock through Restricted Stock Units (RSUs). These RSUs are set to vest in full by November 11, 2026, or at the next annual meeting of stockholders following the grant date. This transaction highlights the company’s ongoing efforts to align management interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc operates in the healthcare industry, primarily focusing on the development and manufacturing of products related to sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions. The company is known for its innovative solutions that improve the quality of life for patients with respiratory disorders.
Average Trading Volume: 1,214,271
Technical Sentiment Signal: Buy
Current Market Cap: A$56.69B
For a thorough assessment of RMD stock, go to TipRanks’ Stock Analysis page.